핵황달 치료 시장 보고서(2025년)

Kernicterus is an infrequent neurological condition that may manifest in newborns experiencing severe jaundice, marked by elevated levels of bilirubin in the bloodstream. Treatment for kernicterus encompasses medical interventions, therapies, and supportive care, primarily administered to infants and children, with the goal of addressing symptoms, complications, and long-term effects, ultimately enhancing the affected individuals' quality of life.

The primary modalities for treating kernicterus include phototherapy, intravenous immunoglobulins (IVIG), blood transfusion, medication, and other supportive measures. Phototherapy involves the application of light, typically specialized lights or lamps, as a medical intervention. This method is employed to address a range of symptoms associated with kernicterus, such as jaundice, unusual eye movements, vomiting, fever, poor feeding, apnea, irritability, seizures, sleepiness, and others. Dosage administration may take various forms, including injections, solutions, and other delivery methods. The end users of these treatments include clinics, hospitals, and other healthcare facilities.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The kernicterus treatment market research report is one of a series of new reports from The Business Research Company that provides kernicterus treatment market statistics, including kernicterus treatment industry global market size, regional shares, competitors with a kernicterus treatment market share, detailed kernicterus treatment market segments, market trends and opportunities, and any further data you may need to thrive in the kernicterus treatment industry. This kernicterus treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The kernicterus treatment market size has grown marginally in recent years. It will grow from $2.98 billion in 2024 to $3.03 billion in 2025 at a compound annual growth rate (CAGR) of 2.0%. The growth in the historic period can be attributed to improvements in neonatal care practices, increased awareness among healthcare professionals, government initiatives for maternal and child health, research funding and clinical trials, collaborations in medical research.

The kernicterus treatment market size is expected to see steady growth in the next few years. It will grow to $3.3 billion in 2029 at a compound annual growth rate (CAGR) of 2.1%. The growth in the forecast period can be attributed to continuous medical education programs, global health policies and initiatives, patient advocacy and support groups, international collaboration in pediatric research, government funding for neonatal health. Major trends in the forecast period include advancements in neonatal jaundice monitoring technologies, introduction of phototherapy devices with enhanced features, development of bilirubin-reducing medications, focus on home-based phototherapy solutions, implementation of bilirubin nomograms and guidelines, integration of telehealth for remote monitoring.

The forecast of 2.1% growth over the next five years reflects a modest reduction of 0.3% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff escalations are likely to burden U.S. neonatal units by driving up the cost of specialized phototherapy systems and albumin infusion products sourced from Sweden and Canada, exacerbating newborn jaundice treatment expenses and increasing NICU operational costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The rising prevalence of neonatal jaundice is expected to drive the growth of the kernicterus treatment market. Neonatal jaundice, commonly observed in newborns, is typically a benign condition marked by yellowing of the skin and eyes. Kernicterus treatment is often applied in cases of neonatal jaundice to manage symptoms and provide supportive care. This treatment involves exchanging the baby's blood with blood containing lower bilirubin levels, which enhances the child's quality of life. For instance, in October 2023, the U.S.-based National Library of Medicine reported that approximately 60% of term infants and 80% of preterm infants develop jaundice within their first week, with about 10% of breastfed infants still showing jaundice at one month. Thus, the widespread occurrence of neonatal jaundice is anticipated to boost the kernicterus treatment market.

Increasing healthcare spending is fueling the growth of the kernicterus treatment market. This type of spending refers to additional investments made in the healthcare sector to address the rising costs associated with expanding or enhancing healthcare services, programs, or infrastructure. Such spending significantly impacts kernicterus treatment by improving the quality and accessibility of care for affected infants and children, leading to better treatment outcomes and an improved quality of life. For example, in November 2023, the Canadian Institute for Health Information reported that total healthcare spending in Canada is expected to reach $344 billion in 2023, or $8,740 per person, marking a 2.8% increase from the prior year's 1.5% growth rate, signaling a strong resurgence in healthcare investment. Consequently, increased healthcare spending is a driving force behind the growth of the kernicterus treatment market.

Key organizations in the cornea treatment market are increasingly focusing on partnerships to expand their reach and strengthen their competitive position. For example, in July 2024, the UCL Department of Medical Physics and Biomedical Engineering, a UK-based institution known for its contributions to medical physics and biomedical engineering research and education, collaborated with UCL Hospitals, a UK-based healthcare provider, to launch NeoSCB. This smartphone application detects severe jaundice in newborns by analyzing images of the sclera (the white part of the eye), offering a non-invasive screening method. The app is particularly valuable in resource-limited settings where traditional jaundice screening devices are expensive. By measuring the yellowness of the sclera, the app correlates this data with bilirubin levels in the blood, achieving a high accuracy rate by successfully identifying 74 out of 79 infants with severe jaundice. Its performance is comparable to conventional methods, such as transcutaneous bilirubinometers, which measure bilirubin through the skin.

In March 2024, Intermountain Health, a US-based nonprofit healthcare system, formed a partnership with Picterus AS to enhance early jaundice detection for newborns. This collaboration aims to improve health outcomes by offering a non-invasive and accessible screening method. Picterus AS, a healthcare technology company based in Norway, specializes in developing technology for screening and monitoring neonatal jaundice.

Major companies operating in the kernicterus treatment market report are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck and Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, AstraZeneca plc., Abbott Laboratories, Sanofi SA, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Johnson and Johnson Private Limited, Baxter International Inc., Grifols S.A, Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Alembic Pharmaceuticals Limited, Lupin Pharmaceuticals Inc., CSL Limited, Glenmark Pharmaceuticals Ltd., Cipla Inc., Torrent Pharmaceuticals Ltd., Octapharma Brasil Ltda, Kedrion S.p.A, Biotest AG, Wockhardt Ltd., Mylan N.V., Cadila Healthcare Ltd., Teva Pharmaceutical Industries Ltd., China Biologic Products Holdings Inc.

North America was the largest region in the kernicterus treatment market in 2024. The regions covered in the kernicterus treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the kernicterus treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The kernicterus treatment market consists of revenues earned by entities by provide kernicterus treatment services such as diagnostic tests, neurological management, medical evaluation and monitoring and exchange transfusion services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Kernicterus Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on kernicterus treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for kernicterus treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The kernicterus treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Treatment: Phototherapy; Intravenous Immunoglobulins (IVIG); Blood Transfusion; Medication; Other Treatments
• 2) By Symptoms: Jaundice; Unusual Eye Movements; Vomiting; Fever; Poor Feeding; Apnoea; Irritability; Seizures; Sleepiness; Other Symptoms
• 3) By Dosage: Injection; Solution; Other Dosages
• 4) By End-Users: Clinic; Hospital; Other End-Users
• Subsegments:
• 1) By Phototherapy: Conventional Phototherapy; Fiberoptic Phototherapy; LED Phototherapy
• 2) By Intravenous Immunoglobulins (IVIG): Standard IVIG Therapy; High-Dose IVIG Therapy
• 3) By Blood Transfusion: Exchange Transfusion; Simple Transfusion
• 4) By Medication: Bilirubin-Lowering Agents; Antioxidants; Neuroprotective Agents
• 5) By Other Treatments: Supportive Care; Nutritional Support; Adjunct Therapies
• Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche Ltd; Merck and Co. Inc.; AbbVie Inc.; Bayer AG; Novartis AG; AstraZeneca plc.; Abbott Laboratories; Sanofi SA; GlaxoSmithKline plc; Takeda Pharmaceutical Company Limited; Johnson and Johnson Private Limited; Baxter International Inc.; Grifols S.A; Sun Pharmaceutical Industries Ltd.; Dr. Reddy's Laboratories Ltd.; Alembic Pharmaceuticals Limited; Lupin Pharmaceuticals Inc.; CSL Limited; Glenmark Pharmaceuticals Ltd.; Cipla Inc.; Torrent Pharmaceuticals Ltd.; Octapharma Brasil Ltda; Kedrion S.p.A; Biotest AG; Wockhardt Ltd.; Mylan N.V.; Cadila Healthcare Ltd.; Teva Pharmaceutical Industries Ltd.; China Biologic Products Holdings Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Kernicterus Treatment Market Characteristics

3. Kernicterus Treatment Market Trends And Strategies

4. Kernicterus Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

• 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Kernicterus Treatment Growth Analysis And Strategic Analysis Framework

• 5.1. Global Kernicterus Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Kernicterus Treatment Market Growth Rate Analysis
• 5.4. Global Kernicterus Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Kernicterus Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Kernicterus Treatment Total Addressable Market (TAM)

6. Kernicterus Treatment Market Segmentation

• 6.1. Global Kernicterus Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Phototherapy
• Intravenous Immunoglobulins (IVIG)
• Blood Transfusion
• Medication
• Other Treatments
• 6.2. Global Kernicterus Treatment Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Jaundice
• Unusual Eye Movements
• Vomiting
• Fever
• Poor Feeding
• Apnoea
• Irritability
• Seizures
• Sleepiness
• Other Symptoms
• 6.3. Global Kernicterus Treatment Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Injection
• Solution
• Other Dosages
• 6.4. Global Kernicterus Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Clinic
• Hospital
• Other End-Users
• 6.5. Global Kernicterus Treatment Market, Sub-Segmentation Of Phototherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Conventional Phototherapy
• Fiberoptic Phototherapy
• LED Phototherapy
• 6.6. Global Kernicterus Treatment Market, Sub-Segmentation Of Intravenous Immunoglobulins (IVIG), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Standard IVIG Therapy
• High-Dose IVIG Therapy
• 6.7. Global Kernicterus Treatment Market, Sub-Segmentation Of Blood Transfusion, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Exchange Transfusion
• Simple Transfusion
• 6.8. Global Kernicterus Treatment Market, Sub-Segmentation Of Medication, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Bilirubin-Lowering Agents
• Antioxidants
• Neuroprotective Agents
• 6.9. Global Kernicterus Treatment Market, Sub-Segmentation Of Other Treatments, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Supportive Care
• Nutritional Support
• Adjunct Therapies

7. Kernicterus Treatment Market Regional And Country Analysis

• 7.1. Global Kernicterus Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Kernicterus Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Kernicterus Treatment Market

• 8.1. Asia-Pacific Kernicterus Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Kernicterus Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Kernicterus Treatment Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Kernicterus Treatment Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Kernicterus Treatment Market

• 9.1. China Kernicterus Treatment Market Overview
• 9.2. China Kernicterus Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Kernicterus Treatment Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Kernicterus Treatment Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Kernicterus Treatment Market

• 10.1. India Kernicterus Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Kernicterus Treatment Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Kernicterus Treatment Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Kernicterus Treatment Market

• 11.1. Japan Kernicterus Treatment Market Overview
• 11.2. Japan Kernicterus Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Kernicterus Treatment Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Kernicterus Treatment Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Kernicterus Treatment Market

• 12.1. Australia Kernicterus Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Kernicterus Treatment Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Kernicterus Treatment Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Kernicterus Treatment Market

• 13.1. Indonesia Kernicterus Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Kernicterus Treatment Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Kernicterus Treatment Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Kernicterus Treatment Market

• 14.1. South Korea Kernicterus Treatment Market Overview
• 14.2. South Korea Kernicterus Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Kernicterus Treatment Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Kernicterus Treatment Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Kernicterus Treatment Market

• 15.1. Western Europe Kernicterus Treatment Market Overview
• 15.2. Western Europe Kernicterus Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Kernicterus Treatment Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Kernicterus Treatment Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Kernicterus Treatment Market

• 16.1. UK Kernicterus Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Kernicterus Treatment Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Kernicterus Treatment Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Kernicterus Treatment Market

• 17.1. Germany Kernicterus Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Kernicterus Treatment Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Kernicterus Treatment Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Kernicterus Treatment Market

• 18.1. France Kernicterus Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Kernicterus Treatment Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Kernicterus Treatment Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Kernicterus Treatment Market

• 19.1. Italy Kernicterus Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Kernicterus Treatment Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Kernicterus Treatment Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Kernicterus Treatment Market

• 20.1. Spain Kernicterus Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Kernicterus Treatment Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Kernicterus Treatment Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Kernicterus Treatment Market

• 21.1. Eastern Europe Kernicterus Treatment Market Overview
• 21.2. Eastern Europe Kernicterus Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Kernicterus Treatment Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Kernicterus Treatment Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Kernicterus Treatment Market

• 22.1. Russia Kernicterus Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Kernicterus Treatment Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Kernicterus Treatment Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Kernicterus Treatment Market

• 23.1. North America Kernicterus Treatment Market Overview
• 23.2. North America Kernicterus Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Kernicterus Treatment Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Kernicterus Treatment Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Kernicterus Treatment Market

• 24.1. USA Kernicterus Treatment Market Overview
• 24.2. USA Kernicterus Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Kernicterus Treatment Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Kernicterus Treatment Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Kernicterus Treatment Market

• 25.1. Canada Kernicterus Treatment Market Overview
• 25.2. Canada Kernicterus Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Kernicterus Treatment Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Kernicterus Treatment Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Kernicterus Treatment Market

• 26.1. South America Kernicterus Treatment Market Overview
• 26.2. South America Kernicterus Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Kernicterus Treatment Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Kernicterus Treatment Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Kernicterus Treatment Market

• 27.1. Brazil Kernicterus Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Kernicterus Treatment Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Kernicterus Treatment Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Kernicterus Treatment Market

• 28.1. Middle East Kernicterus Treatment Market Overview
• 28.2. Middle East Kernicterus Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Kernicterus Treatment Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Kernicterus Treatment Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Kernicterus Treatment Market

• 29.1. Africa Kernicterus Treatment Market Overview
• 29.2. Africa Kernicterus Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Kernicterus Treatment Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Kernicterus Treatment Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Kernicterus Treatment Market Competitive Landscape And Company Profiles

• 30.1. Kernicterus Treatment Market Competitive Landscape
• 30.2. Kernicterus Treatment Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck and Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Bayer AG Overview, Products and Services, Strategy and Financial Analysis

31. Kernicterus Treatment Market Other Major And Innovative Companies

• 31.1. Novartis AG
• 31.2. AstraZeneca plc.
• 31.3. Abbott Laboratories
• 31.4. Sanofi SA
• 31.5. GlaxoSmithKline plc
• 31.6. Takeda Pharmaceutical Company Limited
• 31.7. Johnson and Johnson Private Limited
• 31.8. Baxter International Inc.
• 31.9. Grifols S.A
• 31.10. Sun Pharmaceutical Industries Ltd.
• 31.11. Dr. Reddy's Laboratories Ltd.
• 31.12. Alembic Pharmaceuticals Limited
• 31.13. Lupin Pharmaceuticals Inc.
• 31.14. CSL Limited
• 31.15. Glenmark Pharmaceuticals Ltd.

32. Global Kernicterus Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Kernicterus Treatment Market

34. Recent Developments In The Kernicterus Treatment Market

35. Kernicterus Treatment Market High Potential Countries, Segments and Strategies

• 35.1 Kernicterus Treatment Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Kernicterus Treatment Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Kernicterus Treatment Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer